

ASX:LGP Investor Presentation

27 OCTOBER 2021

Disclaimer



Disclaimer

This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) ("**LGP**") and its activities current as at the date of this presentation. The information in this presentation is of general background and does not purport to be complete or to contain all the information which a prospective investor may require in evaluating a possible investment in LGP or that would be required in a prospectus or a product disclosure statement prepared in accordance with the Corporations Act 2001 (Cth) (Corporations Act).

It should be read in conjunction with LGP's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange, which are available at www.asx.com.au.

This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire LGP's shares or other securities. This document does not constitute or contain an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in LGP.

No liability

The information contained in this document has been prepared in good faith by LGP, however no guarantee representation or warranty expressed or implied is or will be made by any person (including LGP and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document.

To the maximum extent permitted by law, LGP and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in LGP is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

Forward looking statements

Certain information in this document refers to the intentions of LGP, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause LGP's actual results, performance or achievements to differ from those referred to in this document. Accordingly, LGP and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated. Past performance is no guarantee of future performance.

This presentation may contain forward-looking statements including statements regarding our intent, belief or current expectations with respect to LGP's business and operations, market conditions, results of operations and financial condition, specific provisions and risk management practices. When used in this presentation, the words 'likely', 'estimate', 'project', 'intend', 'forecast', 'anticipate', 'believe', 'expect', 'may', 'aim', 'should', 'potential' and similar expressions, as they relate to LGP and its management, are intended to identify forward-looking statements. Forward looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of LGP to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.

Acceptance

By accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as detailed above.



Who we are


Little Green Pharma (ASX:LGP)

- Vertically integrated medicinal cannabis company operating in Australia and Denmark
- Focused solely on pharmaceutical grade cannabis to treat medical conditions
- Australia's first producer and exporter of cannabis medicines
- ~20,000 patients since August 2018
- Exporting EU-GMP recognized cannabis medicines overseas including Germany, France, UK



Corporate Overview

	Capital Structure			
	Current Share Price ¹	\$0.685		
	Shares Outstanding ^{1,2}	235,941,749		
2	Options and Performance Rights on Issue	16,135,536		
	Market Capitalisation (undiluted) ¹	~\$162 million		
	Cash Reserves (30 September 2021)	~\$29.1 million		
	Enterprise Value	~\$133 million		



Shareholders		
Shareholder	Shareholding	Ownership
HANCOCK PROSPECTING PTY LTD ⁴	26.7m	11.3%
ELIXXER LTD ⁵	24.8m	10.5%
MS FLETA JENNIFER SOLOMON	20.2m	8.6%
TIGA TRADING PTY LTD ⁶	16.2m	6.9%
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED ⁷	12.6m	5.3%
BARBRIGHT AUSTRALIA PTY LTD	7.8m	3.3%
MR ANGUS CAITHNESS	6.4m	2.7%
Top 20 shareholders	131.6m	55.8%
Board ownership	28.5m	12.0%

1. As at 24 October 2021

5/

2. 54,034,703 shares are escrowed 24 months from date of listing (20 February 2020) As at 21 September 2021 3. 4.)

Includes associated parties. Holding as advised to market on 6 July 2021 Holding as per register of relevant interests as at 21 September 2021

Includes associated parties. Holding as advised to market on 2 July 2021 6.

Includes Seed Innovations Limited holding of 7,324,796 shares as per register of relevant 7. interests as at 21 September 2021, excludes Hancock Prospecting Pty Ltd and Elixxer Ltd shareholdings.



We are passionate about transforming lives. Our vision is to reimagine cannabis medicines and do extraordinary things for our patients. Our purpose is to solve real patient problems. It's at the heart of everything we do and defines our culture.


We are proud of what we've done and where we're going.

We are Little Green Pharma.



Our Environmental, Social and Governance (ESG) Commitment


LGP solves societal and environmental challenges through core business activities





Our Business Model Captures Value

LGP operates across the entire medicinal cannabis supply chain





Growth Strategy

Little Green Pharma has a track record of sales growth with a clear pathway to increasing margins and driving significant revenue growth in Australia and offshore markets

2

Patient acquisition in Australia

Sales in Australia demonstrate market validity and generate immediate cash flow to support development of international pathways Clear pathway to international sales

Early-mover commercial volumes in international markets the primary mechanism to secure and grow offshore market share 3 Product and drug delivery innovations

Focus on developing unique delivery systems for patients in the future to solve real patient problems and differentiate LGP





Cultivation & Manufacturing Capability

LGP Australia



Indoor GACP cultivation facility capacity ~3 tonnes p.a. biomass (~1.5 tonnes p.a. of dried cannabis flower)

Option to double cultivation capacity with further expansion if necessary

1. LGP has an exclusive agreement with a TGA-GMP certified medicinal cannabis manufacturer who may only terminate the agreement after 22 November 2023 on 12 months' notice.

TGA-GMP manufacturing facility licensed to produce flower, extracts (oils), tinctures and APIs







LGP Denmark



Production capacity of >20 tonnes p.a. biomass (~12 tonnes p.a. of dried cannabis flower)

- 21,500m² glasshouse house cultivation area
 4,000m² post harvest GMP manufacturing facility including laboratory
- Plant and equipment to produce ~12 tonnes p.a. of bulk dried cannabis flower



- World class cannabis cultivation and manufacturing facility
- ✓ GACP cultivation and EUrecognised GMP manufacturing
- ✓ Exported to Australia, Germany and Czech Republic





R&D Pipeline

		INNOVATE Identify key unmet patient needs Sponsor the QUEST Initiative Secure global patent protection	DEVELOP Patient focused drug design Optimisation Scale-up In-house GMP manufacturing 		LAUNCH Rapid path to market access Launch new medicine in Australia (SAS B) & global markets Clinical validation studies Real-world data 	REGISTRATION Market Authorisation (TGA, EMA, FDA) PBS application Image: Constraint of the second sec
		Indication	Pre Clinical	Phase 1	Phase 2	Phase 3
0		Chronic Refractory Pain (Oil Formulation - THC + CBD)				
	SCIENTIFIC VALIDATION STUDIES ¹	HIV (Oil Formulation - CBD)				
		Fibromyalgia (Oil Formulation - THC + CBD)				
		Pain / trauma/spasticity (ARISE Tech -THC + CBD)		 		
	REGULATORY PPROVAL PIPELINE ² larket Authorisation)	Metabolic related conditions (ARISE Tech - THC-plus)				
		OVER-THE-COUNTER S3 Formulation Pilot Study investigating strategic indications		1 1 1 1 1 1 1		

- 1. Studies intended to generate new knowledge (peer reviewed publication) in terms of safety and efficacy; increase brand awareness and consumer confidence of medicinal formulations currently being prescribed to patients.
 - Clinical trials designed to meet the rigorous standards required to achieve regulatory approval and market authorisation (TGA, EMA, FDA) of strategic indications.





The QUEST Initiative aims to be one of the world's largest longitudinal studies investigating the quality of life and health economics of medicinal cannabis on patients with chronic disease

QUEST has recruited **2086 patients** to date and involves **109 doctors** across Australia

2086

Screened 2466 Consented

The QUEST Difference


It's different, and it's BIG:

- Run by the University of Sydney
- Ethics approved
- Discounted medicines (supplied by LGP)
- Examines Quality of Life measures and health economics
- Connects patients with doctors
- Doctor support



Track Record of Patient Access

Strong growth in sales and patients using LGP products



LGP Positioning

LGP is uniquely positioned to supply pharmaceutical-grade cannabis medicines across the globe

Biomass capacity	 LGP's cultivation capacity is >25 tonnes p.a. of cannabis biomass ensuring self sufficiency and long-te security of supply This capacity positions the Company to meet market demand driven by LGP's established brand and distribution channels across the world 	rm
Geographic diversification	 Two strategically located production facilities from which LGP can service Southern and Northern hemisphere markets Both facilities producing EU-GMP recognised cannabis medicines 	
Medicinal cannabis focus	 LGP's sole focus is pharmaceutical-grade cannabis medicines to treat a variety of medical conditions GMP production from Australia and Denmark facilities recognised as the highest quality pharmaceutic grade across target markets 	
Platform to penetrate international markets	 LGP's platform leverages the Company's early mover advantage and brand equity in key international markets The two locations avoid many export/import barriers and requires substantially less logistics resourci than relying on one location Improves distribution strategy by having facilities strategically located 	
Access to best- practices and knowledge	The LGP Group share best-practice cultivation, manufacturing, and pharmaceutical practices and expertise	
		, little reer



Clear Pathway to International Sales


Poland	 ✓ Medezin Sp. z o.o., a subsidiary of Pelion SA, appointed as exclusive distributor in Poland - Pelion SA is the largest operator in the Polish and Lithuanian healthcare sector ✓ Medezin targets to sell Products equivalent to ≥20% of the market for cannabis oil medicines and ≥10% of the Market for high-THC cannabis flower medicines 	
Denmark	 Provides production platform to leverage Company's early mover advantage in key EU markets Additional capacity positions Company to meet market demand driven by LGP's established brand and distribution channels in Europe 	
France	 Primary medicinal cannabis oil supplier to French government 2-year medicinal cannabis trial in partnership with local distributor Intsel Chimos First mover advantage and brand equity in trial anticipated to catalyse the legalisation of medicinal cannabis market 	
Germany	 Medicinal cannabis oils and flower now shipped to Germany for patient use LGP third global medicinal cannabis producer to export medicinal cannabis extract oils to Germany 	
United Kingdom	 Medicinal cannabis oils now shipped to UK for patient use Cannabis flower to be shipped to UK in near term Working with local distributors to distribute medicines 	
Pathfinder Shipments	Pathfinder shipments crucial for gaining intelligence of new market regulatory frameworks and establishing presence and distribution network growth – New Zealand, Lesotho, Brazil	
		10111 1

little reen 17

Market Growth

Australian Market Patient Growth

45,000 active patients forecast to grow to 75,000 by year end¹




1. Freshleaf Analytics H2 2021, Australian Medicinal Cannabis MarketPatient, Product and Pricing Analysis



Australian Addressable Market Growth

2021 market revenue forecast to double from ~\$100M in 2020¹



Australian Total Addressable Market expected to reach A\$1bn²

Freshleaf Analytics H2 2021, Australian Medicinal Cannabis MarketPatient, Product and Pricing Analysis Canaccord Genuity Estimates – 12 May 2021 (based on Worldometer)

1.



Total Addressable Market

LGP's total addressable market globally is estimated at ~\$24bn¹ at maturity


- The global medicinal cannabis markets are experiencing dramatic growth and LGP is one of a few companies world-wide • with the capability to deliver into these new and emerging markets
 - The following countries have been identified as LGP's current target markets based on regulatory frameworks and capability to deliver into key distribution networks

\bigcirc	Country	Population	TAM at maturity	Notes
	Australia	25m	A\$1bn	CBD over the counter could increase this estimate
	France	65m	A\$6bn	Currently illegal (Government medicinal cannabis trial underway)
	Germany	84m	A\$8bn	Already a large market
	United Kingdom	68m	A\$6bn	Restricted by condition. CBD legal and widely available
	Denmark	6m	A\$1bn	Government extended medicinal cannabis trial
	Brazil	213m	A\$2bn	Cultivation illegal, but imported oils are permitted
\bigcirc	TOTAL	461m	A\$24bn	
)			



News Flow – Making Solid Progress

Significant commercial progress as LGP executes growth strategy





Why LGP?

- ✓ Demonstrated business model
- Market opportunity and pathway to capture market share
- Capacity to deliver (vertically integrated)
- ✓ Track record of execution
- The Australian TAM is growing faster than predicted and LGP is in prime position to capitalise
- ✓ Strongly positioned in early overseas markets

Connect

PO Box 690, West Perth Western AUSTRALIA 6872

P: +61 8 6280 0050 E: info@littlegreenpharma.com.au W: littlegreenpharma.com

facebook.com/littlegreenpharma linkedin.com/company/little-green-pharma

PERSONAL PROPERTY LINE

LGP FLOWER

THC 22

Desert Flame